Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58456)- R8 - Effective September 26, 2024

Date Posted: September 26, 2024

This Local Coverage Article (LCA) has been revised under contractor numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY).

Effective Date: September 26, 2024

Summary of Changes:

Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised first sentence #1 to read "muscle-invasive bladder". This revision is due to new covered test that has successfully completed a TA and is effective for 4/19/2022.

Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised first sentence #1 to add "ovarian". This revision is due to new covered test that has successfully completed a TA and is effective for 12/14/2023.

Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised first sentence #1 to add "(neoadjuvant)". This revision is due to new covered test that has successfully completed a TA and is effective for 12/20/2023.

Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised first sentence #2 to add "in patients with a personal history of cancer" and "Natera". Formatting was corrected throughout the article. This revision is due to covered test that has successfully completed a TA and is effective for 5/12/2022.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs  or access it via the CMS MCD.

Last Updated $dateUtil.getDate( $modifieddate , "MMM dd , yyyy" , $locale , $tzone )